Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 3 of 3
Full-Text Articles in Entire DC Network
Inhibitions Of Gsk3Β Modulates Cell Death In Epithelial Ovarian Cancer, Noelle L. Cutter Ph.D., Tyler Walther Bsc, Naeha Pathak
Inhibitions Of Gsk3Β Modulates Cell Death In Epithelial Ovarian Cancer, Noelle L. Cutter Ph.D., Tyler Walther Bsc, Naeha Pathak
Faculty Works: BCES (1999-2023)
Epithelial ovarian cancer is one of the most common gynecological malignancies and the fifth most frequent cause of cancer death in women, affecting over 22,000 women annually. Nearly 15,500 affected women die from this disease annually, and chemoresistance from the commonly prescribed platinum-based drug, carboplatin, is a major contributor to this mortality rate. Previous studies have identified genes with CpG islands that are methylated and transcriptionally silenced in resistant epithelial ovarian cancer patients. One of these genes is GSK3β, an important regulator of apoptosis and cell growth in the Wnt pathway. Thus, understanding the role of GSK3β suppression in chemoresistance …
Abstract 2988: Dok2 Suppression By Methylation Induces Platinum Resistance Via Suppression Of Apoptosis In Ovarian Cancer Cells., Noelle L. Cutter Ph.D., Elena Lum, Michelle Vigliotti, Nilanjana Banerjee, Sitharthan Kamalakaran, Kazimierz O. Wrzeszczynski, Sohail Khan, Nevenka Dimitrova, Douglas A. Levine, Robert Lucito
Abstract 2988: Dok2 Suppression By Methylation Induces Platinum Resistance Via Suppression Of Apoptosis In Ovarian Cancer Cells., Noelle L. Cutter Ph.D., Elena Lum, Michelle Vigliotti, Nilanjana Banerjee, Sitharthan Kamalakaran, Kazimierz O. Wrzeszczynski, Sohail Khan, Nevenka Dimitrova, Douglas A. Levine, Robert Lucito
Faculty Works: BCES (1999-2023)
Ovarian cancers are highly heterogeneous and while chemotherapy is the preferred treatment, many patients are intrinsically resistant or quickly develop resistance. Furthermore, all tumors that recur will become resistant. Recent evidence suggests that epigenetic deregulation may be a key factor in the onset and maintenance of chemoresistance. To examine the ovarian epigenome, we first analyzed a set of 43 primary ovarian tumors and 9 normal ovarian samples. Since therapy response is a significant issue for ovarian cancer patients we analyzed the epigenetic differences that segregate with platinum response. We then associated expression data to identify genes with expression changes potentially …
Abstract 70: A Role For The Chromatin Remodeling Protein Chd3 In Ovarian Cancer Therapy Response, Noelle L. Cutter Ph.D., Nila Banerjee, Michelle Vigliotti, Angel Janevski, Douglas Levine, Robert Lucito, Nevenka Dimitrova
Abstract 70: A Role For The Chromatin Remodeling Protein Chd3 In Ovarian Cancer Therapy Response, Noelle L. Cutter Ph.D., Nila Banerjee, Michelle Vigliotti, Angel Janevski, Douglas Levine, Robert Lucito, Nevenka Dimitrova
Faculty Works: BCES (1999-2023)
Carboplatin and cisplatin are chemotherapeutic agents that are used extensively for treating epithelial ovarian cancer. These drugs can be highly effective, yet tumors are frequently refractory to treatment or become resistant upon tumor relapse. Epigenetic silencing, particularly at promoter regions of genes regulates important cell function and has been associated with all stages of tumor formation and progression and may contribute to therapy response. We analyzed the epigenome of 50 primary ovarian tumors and 12 normal ovarian samples using an array based method previously developed in our lab and associated Affymetrix U133 expression data. We then identified gene candidates that …